Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
NCT ID: NCT00143234
Last Updated: 2021-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1825 participants
INTERVENTIONAL
2004-05-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin
NCT00530946
Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia
NCT00174330
The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.
NCT00656331
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670
Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
NCT00330785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine/atorvastatin single pill
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients currently treated with both amlodipine and atorvastatin or not at blood pressure or lipid level while taking the highest dose of amlodipine or atorvastatin, respectively
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
St Leonards, New South Wales, Australia
Pfizer Investigational Site
Southport, Queensland, Australia
Pfizer Investigational Site
Woolloongabba, Queensland, Australia
Pfizer Investigational Site
Heidelberg, Victoria, Australia
Pfizer Investigational Site
Melbourne, Victoria, Australia
Pfizer Investigational Site
Prahran, Victoria, Australia
Pfizer Investigational Site
Fremantle, Western Australia, Australia
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Pfizer Investigational Site
Recife, Pernambuco, Brazil
Pfizer Investigational Site
Botucatu, São Paulo, Brazil
Pfizer Investigational Site
Campinas, São Paulo, Brazil
Pfizer Investigational Site
Ribeirão Preto, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Santiago, Región Metropolitana, Chile
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Guatemala City, , Guatemala
Pfizer Investigational Site
Pokfulam Road, , Hong Kong
Pfizer Investigational Site
Sai Ying Pun, , Hong Kong
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Mumbai, Nagpada Junction, India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
Jakarta, , Indonesia
Pfizer Investigational Site
Jakarta, , Indonesia
Pfizer Investigational Site
Surabaya, , Indonesia
Pfizer Investigational Site
Jerusalem, , Israel
Pfizer Investigational Site
Jerusalem, , Israel
Pfizer Investigational Site
Rehovot, , Israel
Pfizer Investigational Site
Tel Aviv, , Israel
Pfizer Investigational Site
Tel Litwinsky, , Israel
Pfizer Investigational Site
Amman, , Jordan
Pfizer Investigational Site
Amman, , Jordan
Pfizer Investigational Site
Sasat, , Kuwait
Pfizer Investigational Site
Beirut, , Lebanon
Pfizer Investigational Site
Kubang Kerian, Kelantan, Malaysia
Pfizer Investigational Site
Seremban, Negeri Sembilan, Malaysia
Pfizer Investigational Site
Kuching, Sarawak, Malaysia
Pfizer Investigational Site
Kuala Lumpur, , Malaysia
Pfizer Investigational Site
Kuala Lumpur, , Malaysia
Pfizer Investigational Site
México, D.F, Mexico
Pfizer Investigational Site
Aguascalientes, , Mexico
Pfizer Investigational Site
Metepec, , Mexico
Pfizer Investigational Site
México, , Mexico
Pfizer Investigational Site
Puebla City, , Mexico
Pfizer Investigational Site
San Luis Potosí City, , Mexico
Pfizer Investigational Site
Casablanca, , Morocco
Pfizer Investigational Site
Peshawar, Khyber Pakhtunkhwa, Pakistan
Pfizer Investigational Site
Faisalabad, Punjab Province, Pakistan
Pfizer Investigational Site
Islamabad, Punjab Province, Pakistan
Pfizer Investigational Site
Lahore, Punjab Province, Pakistan
Pfizer Investigational Site
Lima, , Peru
Pfizer Investigational Site
San Juan City, National Capital Region, Philippines
Pfizer Investigational Site
Phippine General Hospital, Taft Avenue, Manila City, Philippines
Pfizer Investigational Site
Filinvest, Alabang, , Philippines
Pfizer Investigational Site
Manila, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Khobar, , Saudi Arabia
Pfizer Investigational Site
Riyadh, , Saudi Arabia
Pfizer Investigational Site
Riyadh, , Saudi Arabia
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Worcester, Cape Province, South Africa
Pfizer Investigational Site
Arcadia, Pretoria, Gauteng, South Africa
Pfizer Investigational Site
Midrand, Johannesburg, Gauteng, South Africa
Pfizer Investigational Site
Sunnyside, Pretoria, Gauteng, South Africa
Pfizer Investigational Site
Chatsworth, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Kwa-Zulu Natal, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Gauteng, , South Africa
Pfizer Investigational Site
Seo-gu, Busan, South Korea
Pfizer Investigational Site
Jung-gu, Daegu, South Korea
Pfizer Investigational Site
Anyang-si, Gyeonggi-do, South Korea
Pfizer Investigational Site
Guri-si, Gyeonggi-do, South Korea
Pfizer Investigational Site
Donggu, Kwangji, South Korea
Pfizer Investigational Site
Gangnam-gu, Seoul, South Korea
Pfizer Investigational Site
Yongdeungpo-gu, Seoul, South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Niao-Sung Hsiang, Kaohsiung, Taiwan
Pfizer Investigational Site
Guei-Shan Shiang, Tau-Yuan Shian, Taiwan
Pfizer Investigational Site
Changhua, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
KHET Rajathevee, Bangkok, Thailand
Pfizer Investigational Site
Bangkok, , Thailand
Pfizer Investigational Site
Chiang Mai, , Thailand
Pfizer Investigational Site
Tunis, , Tunisia
Pfizer Investigational Site
Cebeci, Ankara, Turkey (Türkiye)
Pfizer Investigational Site
Sihhiye, Ankara, Turkey (Türkiye)
Pfizer Investigational Site
Haydarpaşa, Istanbul, Turkey (Türkiye)
Pfizer Investigational Site
Alsancak, İzmir, Turkey (Türkiye)
Pfizer Investigational Site
Talas, Kayseri, Turkey (Türkiye)
Pfizer Investigational Site
Adana, , Turkey (Türkiye)
Pfizer Investigational Site
Antalya, , Turkey (Türkiye)
Pfizer Investigational Site
Diyarbakır, , Turkey (Türkiye)
Pfizer Investigational Site
Istanbul, , Turkey (Türkiye)
Pfizer Investigational Site
Abu Dhabi, , United Arab Emirates
Pfizer Investigational Site
Dubai, , United Arab Emirates
Pfizer Investigational Site
Sharjah city, , United Arab Emirates
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3841024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.